Determining the best aspirin dose for COPD patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This trial aims to evaluate the effectiveness of different doses of aspirin in improving respiratory symptoms in individuals with chronic obstructive pulmonary disease (COPD). Participants will be randomly assigned to receive one of three doses of aspirin (81mg, 162mg, or 325mg) in a crossover design, allowing each participant to experience all treatment doses with a washout period in between. The study will monitor medication adherence and collect blood and urine samples to assess the impact of aspirin on respiratory health. Follow-up visits will occur at two, six, and ten weeks post-randomization to gather comprehensive data on outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥40 years
* Former smoker
* At least 10 pack-year smoking history
* Post-bronchodilator ratio of forced expiratory volume in 1 second to forced vital capacity (FEV1/FVC) \< 0.7

Exclusion Criteria:

* History of myocardial infarction, percutaneous coronary intervention, or stroke
* Currently taking antiplatelet therapy (other than aspirin 81mg) or anticoagulant medication
* Contraindication to aspirin (including low platelet count, hematocrit \<25%, known aspirin-exacerbated respiratory disease, bleeding disorder, history of bleeding or gastrointestinal (GI) ulcer, coagulopathy, or major surgery within 6 weeks before randomization)
* Oral corticosteroids within the past 6 weeks
* Currently taking immunosuppressant medication
* Active malignancy (other than non-melanoma skin cancer)
* Uncontrolled hypertension
* Pregnant or planning pregnancy in the next year
* Plans to move residence away from the immediate area within the next 3 months

Where it's running

• Johns Hopkins Bayview Medical Center
  Baltimore, Maryland, United States Recruiting

Study contacts

• Principal investigator: Ashraf Fawzy, MD, MPH — Johns Hopkins University
• Study coordinator: Wendy Lorizio, MD, MPH
• Email: wlorizi1@jhmi.edu
• Phone: 410-510-2449

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Ensa?fentrine to help prevent COPD flare-ups in adults on standard care

  This study tests whether ensifentrine (MK-5884) can help prevent moderate or severe COPD exacerbations compared with placebo in adults already receiving standard COPD treatment.

  Recruiting at 7 sites Phase 3 Merck Sharp & Dohme LLC · Hialeah Gardens, Florida and 6 other locations · NCT07874815

• GSK Investigational Medicine GSK3862995B: two formulations in healthy adults

  This early-phase study tests two formulations of GSK3862995B in healthy adults to see how the body handles the drug and whether it is safe and tolerable.

  Recruiting Phase 1 GlaxoSmithKline · Cambridge · NCT07789899

• GSK5784283 added to standard COPD therapy vs placebo in moderate to very severe COPD

  This study tests whether adding GSK5784283 to current COPD treatment reduces the rate of COPD flare-ups in adults with eosinophilic COPD and a history of exacerbations.

  Recruiting at 7 sites Phase 3 GlaxoSmithKline · Doral, Florida and 6 other locations · NCT07780669

• GSK5784283 added to standard COPD care versus placebo in adults with moderate to very severe COPD

  This study tests whether adding GSK5784283 to a patient’s current COPD treatment helps reduce COPD flare-ups compared with a placebo in adults with eosinophilic COPD and a history of frequent exacerbations.

  Recruiting at 8 sites Phase 3 GlaxoSmithKline · Cape Coral, Florida and 7 other locations · NCT07780656

• Brenipatide for adults with moderate-to-severe COPD

  This study tests different doses of Brenipatide to see if it is safe and effective for adults with moderate-to-severe COPD, compared with placebo.

  Recruiting at 69 sites Phase 2 Eli Lilly and Company · Birmingham, Alabama and 126 other locations · NCT07759245

• Early depemokimab treatment for COPD with type 2 (eosinophilic) inflammation

  This trial will test whether adding depemokimab early to standard care helps adults with moderate-to-severe COPD who have type 2 (eosinophilic) inflammation.

  Recruiting at 121 sites Phase 3 GlaxoSmithKline · Newport Beach, California and 120 other locations · NCT07177339

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.